BLBenedicte Alexandra Lie

Benedicte Alexandra Lie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benedicte Alexandra Lie has a total of 251 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Exploring differences in protein cargo of extracellular vesicles from ME/CFS patient plasma compared to healthy controls

    by Anne Rydland, Elena Støvring Yran, Tuula A. Nyman, Elin Bolle Strand, Anne-Marie Siebke Trøseid, Reidun Øvstebø, Fatima Heinicke, Benedicte A. Lie, Marte K. Viken


  • Open Access

    Novel Genomic Risk Loci shared between Juvenile Idiopathic Arthritis and other HLA-associated Autoimmune Diseases

    by Hamid Khoshfekr Rudsari, Piotr Jaholkowski, Srijana Bastakoti, Vera Fominykh, Kristine Løkås Haftorn, Alexey A. Shadrin, Benedicte A. Lie, Ole A. Andreassen, Helga Sanner

    Objectives: To investigate genetic architecture and identify novel risk loci shared between juvenile idiopathic arthritis (JIA) and other human leukocyte antigen (HLA)-associated autoimmune diseases (AIDs) by leveraging genome-wide association studies (GWAS) data. Methods: We analyzed GWAS summary statistics from over two million participants (123,997 cases and 1,843,249 controls) of European ancestry across multiple AIDs including JIA, autoimmune thyroid disease (AITD), celiac disease, inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis (Ps), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and type 1 diabetes (T1D). The conjunctional false discovery rate (conjFDR) method was employed to identify shared genetic loci, followed by functional annotation and pathway analysis. Results: We identified 46 novel loci shared between JIA and various AIDs: 17 with AITD, 16 with RA, 13 with IBD, five each with MS and Ps, four with SLE, and seven with T1D. Notable shared risk genes included BACH2, UBASH3A, IRF4, IL12A-AS1, ETS1, PSMD14, FOXK1, NEK6, SP140, TNIP1, VAV3, CYP20A1, DNMT3A, LAX1, CASC15, ZC3H12C, KALRN, TBC1D1, PIK3CB, ANXA6 , and HIF1A . Functional annotation revealed 170 nonsynonymous exonic variants and 478 potentially deleterious variants (CADD score > 12.37). Gene Ontology analysis consistently highlighted enrichment of T cell-related processes and immune system regulation pathways. Conclusion: This study expands the understanding of genetic architecture in JIA by identifying novel risk loci shared with other AIDs. The extensive genetic overlap and shared biological pathways, particularly in T cell-mediated immunity, suggest common pathogenic mechanisms and potential therapeutic targets across multiple autoimmune conditions.

  • Open Access

    Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes

    by Anne Rydland, Fatima Heinicke, Tuula A. Nyman, Anne-Marie Siebke Trøseid, Siri T. Flåm, Maria Stensland, Johanna Gehin, Joakim Eikeland, Reidun Øvstebø, Maria Dahl Mjaavatten, et al.

    Extracellular vesicles (EVs) are implicated in rheumatoid arthritis (RA) but have mainly been assessed in RA patients taking disease modifying anti-rheumatic drugs. EVs are nanoparticles important in cell-cell communication and their molecular cargo are biomarker candidates. We characterized the protein profiles of EVs from blood plasma from newly diagnosed, treatment naïve RA patients (N = 32) and compared them to healthy controls (N = 20), by size exclusion chromatography-based EV enrichment coupled with high-resolution quantitative proteomics. The RA patients had higher EV concentration and larger EVs than controls. A total of 682 EV proteins were reliably quantified, and the overall profiles were distinctly different between patients and controls. Specifically, 26 proteins were significantly upregulated and 31 downregulated in RA patients, with several proteins acting in inflammatory networks and with immunologically important upstream regulators. The RA associated EVs appear, based on the tissue expression of their cargo proteins, to originate mainly from hepatocytes or immune cells, like neutrophils. Interestingly, the strongest RA associated EV proteins were inflammatory molecules, like SAA1 and S100A9, already suggested as biomarkers in RA. Furthermore, the RA associated EV proteins were generally not correlated with total serum protein levels, stressing the importance of EV transport of inflammatory proteins in RA pathogenesis.


  • Open Access

    Gene Expression Correlates with Disability and Pain Intensity in Patients with Chronic Low Back Pain and Modic Changes in a Sex-Specific Manner

    by Maria Dehli Vigeland, Siri Tennebø Flåm, Magnus Dehli Vigeland, Manuela Zucknick, Monica Wigemyr, Lars Christian Haugli Bråten, Elisabeth Gjefsen, John-Anker Zwart, Kjersti Storheim, Linda Margareth Pedersen, et al.

    Chronic low back pain (cLBP) lacks clear physiological explanations, and the treatment options are of limited effect. We aimed to elucidate the underlying biology of cLBP in a subgroup of patients with Modic changes type I (suggestive of inflammatory vertebral bone marrow lesions) by correlating gene expression in blood with patient-reported outcomes on disability and pain intensity and explore sex differences. Patients were included from the placebo group of a clinical study on patients with cLBP and Modic changes. Blood was collected at the time of inclusion, after three months, and after one year, and gene expression was measured at all time points by high-throughput RNA sequencing. The patients reported disability using the Roland–Morris Disability Questionnaire, and pain intensity was assessed as a mean of three scores on a 0–10 numeric rating scale: current LBP, worst LBP within the last two weeks, and mean LBP within the last two weeks. The gene expression profiles were then correlated to the reported outcomes. Changes in gene expression over time correlated significantly with changes in both disability and pain. The findings showed distinct patterns in men and women, with negligible overlap in correlated genes between the sexes. The genes involved were enriched in immunological pathways, particularly T cell receptor complex and immune responses related to neutrophils. Several of the genes harbour polymorphisms that previously have been found to be associated with chronic pain. Taken together, our results indicate gender differences in the underlying biology of disability and pain intensity in patients with low back pain.


  • Open Access

    Human thymic putative CD8αα precursors exhibit a biased TCR repertoire in single cell AIRR-seq

    by Marte Heimli, Siri Tennebø Flåm, Hanne Sagsveen Hjorthaug, Pål Marius Bjørnstad, Maria Chernigovskaya, Quy Khang Le, Xavier Tekpli, Victor Greiff, Benedicte Alexandra Lie

    Thymic T cell development comprises T cell receptor (TCR) recombination and assessment of TCR avidity towards self-peptide-MHC complexes presented by antigen-presenting cells. Self-reactivity may lead to negative selection, or to agonist selection and differentiation into unconventional lineages such as regulatory T cells and CD8 $$\mathrm{\alpha \alpha }$$ α α T cells. To explore the effect of the adaptive immune receptor repertoire on thymocyte developmental decisions, we performed single cell adaptive immune receptor repertoire sequencing (scAIRR-seq) of thymocytes from human young paediatric thymi and blood. Thymic PDCD1+ cells, a putative CD8 $$\mathrm{\alpha \alpha }$$ α α T cell precursor population, exhibited several TCR features previously associated with thymic and peripheral ZNF683+ CD8 $$\mathrm{\alpha \alpha }$$ α α T cells, including enrichment of large and positively charged complementarity-determining region 3 (CDR3) amino acids. Thus, the TCR repertoire may partially explain the decision between conventional vs. agonist selected thymocyte differentiation, an aspect of importance for the development of therapies for patients with immune-mediated diseases.


  • Open Access

    Long-Term Use of Amoxicillin Is Associated with Changes in Gene Expression and DNA Methylation in Patients with Low Back Pain and Modic Changes

    by Maria Dehli Vigeland, Siri Tennebø Flåm, Magnus Dehli Vigeland, Ansgar Espeland, Manuela Zucknick, Monica Wigemyr, Lars Christian Haugli Bråten, Elisabeth Gjefsen, John-Anker Zwart, Kjersti Storheim, et al.

    Long-term antibiotics are prescribed for a variety of medical conditions, recently including low back pain with Modic changes. The molecular impact of such treatment is unknown. We conducted longitudinal transcriptome and epigenome analyses in patients (n = 100) receiving amoxicillin treatment or placebo for 100 days in the Antibiotics in Modic Changes (AIM) study. Gene expression and DNA methylation were investigated at a genome-wide level at screening, after 100 days of treatment, and at one-year follow-up. We identified intra-individual longitudinal changes in gene expression and DNA methylation in patients receiving amoxicillin, while few changes were observed in patients receiving placebo. After 100 days of amoxicillin treatment, 28 genes were significantly differentially expressed, including the downregulation of 19 immunoglobulin genes. At one-year follow-up, the expression levels were still not completely restored. The significant changes in DNA methylation (n = 4548 CpGs) were mainly increased methylation levels between 100 days and one-year follow-up. Hence, the effects on gene expression occurred predominantly during treatment, while the effects on DNA methylation occurred after treatment. In conclusion, unrecognized side effects of long-term amoxicillin treatment were revealed, as alterations were observed in both gene expression and DNA methylation that lasted long after the end of treatment.


  • Open Access

    HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases

    by Marthe Kirkesæther Brun, Kristin Hammersbøen Bjørlykke, Marte K. Viken, Grethe‐Elisabeth Stenvik, Rolf A. Klaasen, Johanna E. Gehin, David John Warren, Joseph Sexton, Øystein Sandanger, Tore K. Kvien, et al.

    BackgroundImmunogenicity to tumour necrosis factor inhibitors is a significant clinical problem leading to treatment failure and adverse events. The study aimed to assess human leukocyte antigen (HLA) associations with anti-drug antibody (ADAb) formation to infliximab. MethodsImmune-mediated inflammatory disease patients on infliximab therapy (n = 612) were included. Neutralising ADAb were assessed with a drug-sensitive assay. Next generation sequencing-based HLA typing was performed. ResultsOverall, 147 (24%) patients developed ADAb. Conditional analyses indicated HLA-DQB1 (p = 1.4 x 10(-6)) as a primary risk locus. Highest risk of ADAb was seen when carrying at least one of the HLA-DQ2 haplotypes; DQB1*02:01-DQA1*05:01 or DQB1*02:02-DQA1*02:01 (OR 3.18, 95% CI 2.15-4.69 and p = 5.9 x 10(-9)). Results were consistent across diseases and when adjusting for concomitant immunomodulator. Computational predictions indicated that these HLA-DQ2 haplotypes bind to peptide motifs from infliximab light chain. ConclusionA genome-wide significant association between two HLA-DQ2 haplotypes and the risk of ADAb formation to infliximab was identified, suggesting that HLA-DQ2 testing may facilitate personalised treatment decisions.


  • Open Access

    Small extracellular vesicles have distinct CD81 and CD9 tetraspanin expression profiles in plasma from rheumatoid arthritis patients

    by Anne Rydland, Fatima Heinicke, Siri T. Flåm, Maria D. Mjaavatten, Benedicte A. Lie

    Extracellular vesicles (EVs) are implicated in the pathogenesis of rheumatoid arthritis (RA) but little is known about the composition of specific small EV (sEV) subpopulations. This study aimed to characterize the CD63, CD81 and CD9 tetraspanin profile in the membrane of single EVs in plasma from treatment naïve RA patients and assess potential discrepancies between methotrexate (MTX) responder groups. EVs isolated from plasma were characterized using transmission electron microscopy, and detection of surface markers (CD63, CD81 and CD9) on single EVs was performed on the ExoView platform. All RA patients (N = 8) were newly diagnosed, treatment naïve, females, ACPA positive and former smokers. The controls (N = 5) were matched for age and gender. After three months of MTX treatment, responders (N = 4) were defined as those with ΔDAS28 > 1.2 and DAS28 ≤ 3.2 post-treatment. The isolated EVs were 50–200 nm in size. The RA patients had a higher proportion of both CD9 and CD81 single positive sEVs compared to healthy controls, while there was a decrease in CD81/CD9 double positive sEVs in patients. Stratification of RA patients into MTX responders and non-responders revealed a distinctly higher proportion of CD81 single positive sEVs in the responder group. The proportion of CD81/CD9 double positive sEVs (anti-CD9 captured) was lower in the non-responders, but increased upon 3 months of MTX treatment. Our exploratory study revealed distinct tetraspanin profiles in RA patients suggesting their implication in RA pathophysiology and MTX treatment response.


  • Open Access

    Multimodal human thymic profiling reveals trajectories and cellular milieu for T agonist selection

    by Marte Heimli, Siri Tennebø Flåm, Hanne Sagsveen Hjorthaug, Don Trinh, Michael Frisk, Karl-Andreas Dumont, Teodora Ribarska, Xavier Tekpli, Mario Saare, Benedicte Alexandra Lie

    To prevent autoimmunity, thymocytes expressing self-reactive T cell receptors (TCRs) are negatively selected, however, divergence into tolerogenic, agonist selected lineages represent an alternative fate. As thymocyte development, selection, and lineage choices are dependent on spatial context and cell-to-cell interactions, we have performed Cellular Indexing of Transcriptomes and Epitopes by sequencing (CITE-seq) and spatial transcriptomics on paediatric human thymu​​s. Thymocytes expressing markers of strong TCR signalling diverged from the conventional developmental trajectory prior to CD4+ or CD8+ lineage commitment, while markers of different agonist selected T cell populations (CD8αα(I), CD8αα(II), T(agonist), Treg(diff), and Treg) exhibited variable timing of induction. Expression profiles of chemokines and co-stimulatory molecules, together with spatial localisation, supported that dendritic cells, B cells, and stromal cells contribute to agonist selection, with different subsets influencing thymocytes at specific developmental stages within distinct spatial niches. Understanding factors influencing agonist T cells is needed to benefit from their immunoregulatory effects in clinical use.


  • Open Access

    Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis

    by Liv B. Gansmo, Benedicte A. Lie, Marthe T. Mæhlen, Lars Vatten, Pål Romundstad, Kristian Hveem, Per E. Lønning, Stian Knappskog